| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2564 | 2011 |
| Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth KM Nieman, HA Kenny, CV Penicka, A Ladanyi, R Buell-Gutbrod, ... Nature medicine 17 (11), 1498-1503, 2011 | 2223 | 2011 |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008 | 1192 | 2008 |
| Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics BT Hennessy, AM Gonzalez-Angulo, K Stemke-Hale, MZ Gilcrease, ... Cancer research 69 (10), 4116-4124, 2009 | 1052 | 2009 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 901 | 2015 |
| Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer V Abkevich, KM Timms, BT Hennessy, J Potter, MS Carey, LA Meyer, ... British journal of cancer 107 (10), 1776-1782, 2012 | 744 | 2012 |
| Does this patient have strep throat? MH Ebell, MA Smith, HC Barry, K Ives, M Carey Jama 284 (22), 2912-2918, 2000 | 540 | 2000 |
| Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer BTJ Hennessy, KM Timms, MS Carey, A Gutin, LA Meyer, DD Flake, ... Journal of Clinical Oncology 28 (22), 3570-3576, 2010 | 441 | 2010 |
| A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer LA Brotto, Y Erskine, M Carey, T Ehlen, S Finlayson, M Heywood, J Kwon, ... Gynecologic oncology 125 (2), 320-325, 2012 | 333 | 2012 |
| Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010 MS Anglesio, MS Carey, M Köbel, H MacKay, DG Huntsman Gynecologic oncology 121 (2), 407-415, 2011 | 303 | 2011 |
| Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. GP Browman, TE Newman, EA Mohide, ID Graham, MN Levine, ... Journal of clinical oncology 16 (3), 1226-1231, 1998 | 284 | 1998 |
| Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer AM Gonzalez-Angulo, K Stemke-Hale, SL Palla, M Carey, R Agarwal, ... Clinical Cancer Research 15 (7), 2472-2478, 2009 | 263 | 2009 |
| A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers BT Hennessy, Y Lu, AM Gonzalez-Angulo, MS Carey, S Myhre, Z Ju, ... Clinical proteomics 6, 129-151, 2010 | 259 | 2010 |
| Characteristics of women undergoing repeat induced abortion WA Fisher, SS Singh, PA Shuper, M Carey, F Otchet, D MacLean-Brine, ... CMAJ 172 (5), 637-641, 2005 | 242 | 2005 |
| General health and psychological symptom status in pregnancy and the puerperium: what is normal? F Otchet, MS Carey, L Adam Obstetrics & Gynecology 94 (6), 935-941, 1999 | 228 | 1999 |
| Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium MS Carey, GJ O'Connell, CR Johanson, MD Goodyear, KJ Murphy, ... Gynecologic oncology 57 (2), 138-144, 1995 | 211 | 1995 |
| The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada … BBY Ma, A Oza, E Eisenhauer, G Stanimir, M Carey, W Chapman, E Latta, ... International Journal of Gynecologic Cancer 14 (4), 2004 | 203 | 2004 |
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 … D Stark, M Nankivell, E Pujade-Lauraine, G Kristensen, L Elit, M Stockler, ... The lancet oncology 14 (3), 236-243, 2013 | 189 | 2013 |
| Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer R Agarwal, AM Gonzalez-Angulo, S Myhre, M Carey, JS Lee, J Overgaard, ... Clinical cancer research 15 (11), 3654-3662, 2009 | 186 | 2009 |
| Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer A Covens, M Carey, P Bryson, S Verma, MFK Fung, M Johnston Gynecologic oncology 85 (1), 71-80, 2002 | 183 | 2002 |
